{"id":"doi:10.1038/s41591-024-03015-5","kind":"article","title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","authors":["Helen Martina Colhoun","Ildiko Lingvay","Paul Brown","John Eric Deanfield","Kirstine Brown‐Frandsen","Steven E. Kahn","Jorge Plutzky","Koichi Node","Alexander N. Parkhomenko","Lars Rydén","John P.H. Wilding","Johannes F.E. Mann","Katherine R. Tuttle","Thomas Idorn","Naveen Rathor","Abraham Michael Lincoff"],"author_count":16,"year":2024,"published":"2024-05-25","venue":"Nature Medicine","cited_by":237,"doi":"10.1038/s41591-024-03015-5","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41591-024-03015-5","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41591-024-03015-5","updated":null,"pmid":"38796653","pmcid":"PMC11271413","openalex_id":"W4399012115","pdf_url":"https://europepmc.org/articles/PMC11271413/pdf","abstract":"Abstract The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide ( n = 8,803) versus placebo ( n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min −1 1.73 m − 2 , persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min −1 1.73 m − 2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min −1 1.73 m − 2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min −1 1.73 m − 2 . These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes. ClinicalTrials.gov identifier: NCT03574597 .","abstract_license":"CC-BY (publisher license, via OpenAlex)","license":"cc-by","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Chronic Kidney Disease and Diabetes"],"details":null,"provenance":"openalex+europepmc","attribution":"Abstract of \"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial\" by Helen Martina Colhoun, Ildiko Lingvay, Paul Brown et al., https://doi.org/10.1038/s41591-024-03015-5, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}